OUR COMMITMENTS TO PAEDIATRIC HIV: RESEARCH PARTNERS SHARE NEW DOLUTEGRAVIR DATA ON TREATMENT OF HIV-INFECTED CHILDREN
Media contacts
For our corporate press office, email: Rachel Jaikaran
OR call +44 7823 523 755
For US-specific media enquiries, email: Audrey Abernathy
OR call +1 919 605 4521
London, UK, 14 March 2019 - Last week at CROI 2019 in Seattle, our clinical trial partners from IMPAACT and PENTA networks presented new clinical data on paediatric dolutegravir from the P1093 and ODYSSEY studies:
- PK and 4 week outcomes of dolutegravir dispersible tablets in HIV-infected children (IMPAACT, P1093 study)
- Adult DTG 50mg film-coated tablets in children living with HIV weighing 20 - <25kg (PENTA, ODYSSEY PK sub-study)
These new data provide more needed information and bring the joint IMPAACT-PENTA-ViiV Healthcare team a step closer to achieving our target to deliver on our commitment towards the FDA & EU regulatory submissions.
Further data is needed for the regulatory dossiers to meet on stringent regulatory authority expectations. This continues to be a key priority for ViiV Healthcare and the IMPAACT and PENTA networks through 2019. We will continue to update our partners and the community as we progress towards our goal.
If you get any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the GSK Reporting Tool link https://gsk.public.reportum.com/. By reporting side effects, you can help provide more information on the safety of this medicine.
If you are from outside the UK, you can report adverse events to GSK/ ViiV by selecting your region and market, here.
